PNGase F

GlycoPath Inc. Launches Glycan Imaging Kit for Glycoproteomic Analysis of Clinical and Research Samples

Retrieved on: 
Tuesday, November 9, 2021
Histology, Society, Protein, View, Multimedia, Research, PNGase F, Conference, Glycoprotein, Protein folding, Video game console, Fine chemical

Kits are available in two sizes and can be purchased through the GlycoPath website.

Key Points: 
  • Kits are available in two sizes and can be purchased through the GlycoPath website.
  • This is an out of the box solution for N-glycan imaging analysis designed for both new and experienced users."
  • The official launch of this kit was announced at the 69th American Society of Mass Spectrometry Annual Conference held October 31-November 4, 2021 in Philadelphia, PA.
  • From a researcher point of view, the provided protocol is very straightforward, and the kit is designed to make N-Glycan Imaging even simpler."

M6P Therapeutics to Present at the 17th Annual International Congress on Neuronal Ceroid Lipofuscinosis

Retrieved on: 
Friday, October 8, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Linda, Person, Epilepsy, Endocytosis, N, Nervous system, Therapy, LSD, Dementia, CLN3, Plasmid, Endoglycosidase H, Batten disease, A-DNA, Neuronal ceroid lipofuscinosis, CLN2, PNGase F, Glycogen storage disease, Drug development, Lysosome, Mannose, Neuron, Neurodegeneration, Washington University in St. Louis, Eric, M6P, Prevalence, Severe cognitive impairment, NCLS, Enzyme, Communication, International, NCL, Autosome, International Congress on Tuberculosis, Disease, Patient, Enzyme replacement therapy, TPP1, Research, Technology, Phosphorylation, Pharmaceutical industry, Fine chemical

Neuronal ceroid lipofuscinosis type 2 (CLN2) is a neurodegenerative disorder caused by autosomal recessive mutations in the TPP1 gene, leading to the deficiency of TPP1, a lysosomal enzyme.

Key Points: 
  • Neuronal ceroid lipofuscinosis type 2 (CLN2) is a neurodegenerative disorder caused by autosomal recessive mutations in the TPP1 gene, leading to the deficiency of TPP1, a lysosomal enzyme.
  • Batten disease originally referred specifically to the juvenile and most common form of neuronal ceroid lipofuscinosis (NCL), now known as CLN3 .
  • Most forms are inherited in an autosomal recessive manner; however, autosomal dominant inheritance has been reported in one adult-onset form (neuronal ceroid lipofuscinosis 4B).
  • M6P Therapeutics mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community.